In a nutshell This study investigated the potential benefits of radiotherapy (RT) for the treatment of patients with advanced-stage Hodgkin lymphoma (HL) who have achieved a complete metabolic response (CMR) after ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-based chemotherapy. The data showed no significant difference in patient outcomes...
Read More
In a nutshell The study aimed to investigate if very low-dose radiotherapy (VLDRT) was effective in treating patients with indolent (painless) non-Hodgkin lymphoma (NHL). This study concluded that this treatment can be effective in these patients. Some background Radiotherapy (RT) is an important treatment in managing patients...
Read More
In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new biological therapy drugs. This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy. Some background...
Read More
In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new biological drugs. This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy. Some background Treatments for...
Read More
In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new targeted therapy drugs. This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy. Some background Treatments for...
Read More
In a nutshell This study compared the effectiveness and safety of talimogene laherparepvec (Imlygic; T-VEC) plus surgery versus surgery alone for the treatment of patients with resectable advanced stage (III or IV) melanoma. The data showed that T-VEC plus surgery was safe and effective for these patients. Some background Melanoma is an aggressive...
Read More
In a nutshell This study investigated the effectiveness and safety of fixed-duration treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with previously untreated chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that fixed-duration treatment with ibrutinib plus venetoclax was...
Read More
In a nutshell This study compared the surgical, functional, and oncological outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer (PCa) with a large prostate volume. The study found that RARP was associated with better surgical,...
Read More
In a nutshell This study evaluated how long estrogen should be used during artificial cycle frozen embryo transfer (FET). It found that stopping estrogen at 6 weeks of pregnancy reduced miscarriages compared to continuing to 12 weeks. Stopping at 6 weeks also led to fewer pregnancy complications. Some background FET is a common infertility...
Read More
In a nutshell This study aimed to evaluate brentuximab vedotin (BV; Adcedris) and bendamustine (Treanda) treatment in pediatric patients with relapsed/refractory (r/r) Hodgkin Lymphoma (HL). This study concluded that this treatment combination was safe and effective in these patients. Some background HL is a common cancer...
Read More
In a nutshell This study evaluated the long-term benefits and risks of trastuzumab (Herceptin) plus chemotherapy in patients with early-stage HER2-positive (+) breast cancer (BC). The data showed that trastuzumab added to chemotherapy reduced the risk of BC recurrence and death for these patients. Some background BC is classified into different...
Read More
In a nutshell This study evaluated the cardiovascular (CV; heart and blood vessels) side effects in patients with chronic lymphocytic leukemia (CLL) who received acalabrutinib (Calquence) treatment. The data showed that the occurrence of CV side effects with acalabrutinib treatment is very low in patients with CLL. Some background CLL is a type of...
Read More
